Friday, August 13, 2021 Daily Archives

Exploring On-Column mAb Aggregate Formation and Self-Generated On-Column pH Gradients with Cation Exchange Resins

by

This webcast features: William H. Rushton, Process Chromatography Support Scientist, Bio-Rad Laboratories The formation of aggregates is a common occurrence during monoclonal antibody (mAb) purification and can happen for several reasons. Aggregates are undesirable due to the possibility of altered pharmacodynamics, pharmacokinetics, and/or increased immunogenicity. Generally, the formation of aggregates is shown to be product or process related. A high-resolution cation exchange (CEX) resin, Nuvia HR-S, has been shown to reduce aggregate content with high monomer recovery. In this webcast,…

August 13, 2021

Moderna inks deal to build mRNA facility in Canada

by

Moderna has signed a Memorandum of Understanding with the Canadian government to construct an mRNA vaccine manufacturing facility. The Memorandum of Understanding (MoU) will see Moderna build a messenger RNA (mRNA) vaccine plant, which aims to provide Canada with support to respond rapidly to current and future pandemics. While it is not yet confirmed where the plant will be located in Canada, the firm is looking to replicate this business model in other countries. “As a company, we are committed…

August 13, 2021

Rentschler doubling commercial capacity through US expansion

by

Driven by demand for an increasing complexity and diversity of modalities, CDMO Rentschler has broken ground on a second facility in Milford, Massachusetts. German contract development and manufacturing organization (CDMO) Rentschler laid down its US roots in 2019 when it bought a biomanufacturing facility from the now defunct Shire in January 2019 in Milford, Massachusetts – about 20 miles southwest of Boston. Now the firm has begun expanding its presence, breaking ground on facility adjacent to the ex-Shire plant set to…

August 13, 2021

Ginkgo and Aldevron partnership delivers tenfold mRNA improvement

by

The partnership with Aldevron has led to an mRNA breakthrough with their manufacturing approach proving 10 times more efficient than the previous process, says Ginkgo Bioworks. The collaboration, which was formed earlier in 2021, has resulted in what the firms have called a breakthrough for Vaccinia Capping Enzymes (VCEs) used to manufacture messenger RNA (mRNA) vaccines. VCEs cause the human body to recognize the RNA as something it can translate into a protein, which is essentially how the vaccine works.…

August 13, 2021